Clinical Findings-Physical examination of the rabbit revealed bilateral conjunctivitis, hypersalivation, and severe signs of CNS dysfunction such as incoordination, intermittent myoclonic seizures, and opisthotonus. Results of hematologic and serum biochemical analyses revealed Selleck Ruboxistaurin only lymphopenia, a relative monocytosis, and an increase in serum activity of creatine phosphokinase and serum concentration of total protein.
Serum antibodies against Encephalitozoon cuniculi and Toxoplasma gondii were not detected.
Treatment and Outcome-Despite IV administration of crystalloid fluids and treatment with antimicrobials, vitamin B complex, nutritional support, and prednisolone, the condition of
the rabbit deteriorated; it was euthanized 7 days after admission. Histologic evaluation of brain tissue revealed lesions characteristic C59 mouse of severe, diffuse, nonsuppurative meningoencephalitis and a few large, eosinophilic, intranuclear inclusion bodies in neurons and glial cells. The DNA of human herpesvirus-1 was detected in the nuclei of glial cells, lymphocytes, and neurons by means of in situ hybridization. The rabbit’s owner, who reported having had a severe labial and facial herpesvirus infection 5 days before the onset of clinical signs in the rabbit, was suspected to be the origin of infection for the rabbit.
Clinical Relevance-Human herpesvirus-1 may be transmissible from humans to rabbits, and infection with this virus should be considered as a differential diagnosis in rabbits with CNS signs of disease. (J Am Vet Med Assoc 2009;1235:66-69)”
“Objectives: Changes in the lipid profile have been described in patients with rheumatoid
arthritis (RA) following therapy with tumor necrosis factor (TNF)-alpha NSC 697286 blocking agents. However, thus far, results have been inconsistent. Therefore, we investigated changes in lipid levels after TNFalpha blocking therapy using meta-analysis of published data.
Methods: The literature was searched to identify studies assessing changes in total cholesterol (TC), high-density lipoprotein cholesterol (HDLc), low-density lipoprotein cholesterol, triglycerides, atherogenic index (ie, TC/HDLc ratio), and apolipoprotein levels in response to TNF-alpha blocking therapy. Weighted mean levels of lipids at different time points and subsequent changes in these lipid levels between these time points were calculated with multivariate linear mixed models.
Results: Data were available on TC in 15 studies encompassing 766 RA patients and on HDLc in 14 studies encompassing 736 RA patients. TC increased significantly (maximum increase of 10%) and HDLc increased significantly in the first 2 to 6 weeks of therapy (maximum increase of 7%), after which it remained more or less stable. The atherogenic index did not significantly change over time.